CorMedix Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CRMD | NVCT | LXRX | SLDB | RLMD | MNKD | |
|---|---|---|---|---|---|---|
| Market cap | 441.16M | 602.94M | 658.53M | 699.11M | 444.81M | 1.26B |
| P/E (TTM) | 2.8 | — | — | — | — | — |
| Forward P/E | 16.2 | -19.2 | -7.8 | -3.8 | -10.2 | 29.1 |
| Price/book | 1.0 | 5.1 | 3.8 | 2.9 | 2.2 | -18.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −47.50% | +225.75% | +3.50% | +54.69% | +59.77% | −38.45% |
| Today | +1.80% | −4.50% | +1.37% | +3.82% | −2.34% | +5.36% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CRMD news ›Cinven to Acquire Women’s Health Drugmaker Theramex for $2.6B
International private equity firm Cinven has agreed to acquire women’s health pharmaceutical company Theramex for $2.6 billion from Carlyle and PAI Partners. Theramex develops and commercializes treatments across women’s health, includin
CRMD Slides As Traders React To Sharp Volume Shift
CorMedix Inc. stocks have been trading down by -24.81 percent amid heightened concern over its latest regulatory and clinical developments. Market Insights For Active CRMD Traders Weekly chart shows CorMedix Inc. dropping from the low $8s…
CRMD Slides Sharply As Traders Eye Support Levels
CorMedix Inc. stocks have been trading down by -24.81 percent amid heightened concern over its latest clinical trial developments. Market Insights For Active CRMD Traders Price has dropped from above $8 to the mid-$5s this week, putting…
CorMedix Inc (NASDAQ:CRMD) Stock Has Consensus Price Target of $15.00
Shares of CorMedix Inc (NASDAQ:CRMD – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a…
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has initiated the proces... Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets REDWOOD CITY,…
CorMedix Inc (CRMD) – What Are Analysts Saying About This Stock?
Posted by Defense World Staff on Oct 28th, 2026 Read Our Latest Analysis on CRMD NASDAQ:CRMD opened at $8.00 on Wednesday. CorMedix has a 1 year low of $6.13 and a 1 year high of $13.02. The stock’s 50 day simple moving average is $7.87…
Contrasting CorMedix (NASDAQ:CRMD) & InMed Pharmaceuticals (NASDAQ:INM)
Posted by Tristan Rich on Oct 22nd, 2026 InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) and CorMedix (NASDAQ:CRMD – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two…
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and... CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference PARSIPPANY,…
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
The FDA’s acceptance of this supplemental application for Priority Review is an important regulatory milestone for CorMedix, REZZAYO, and for patients who remain at risk for invasive fungal disease,” ... Cormedix Announces FDA Acceptance…
Cormedix gets FDA priority review for Rezzayo label expansion
CorMedix (CRMD) stock is in focus on Monday as the FDA grants priority review seeking a label expansion for the company's Rezzayo antifungal drug. Read more here. - CorMedix (CRMD) on Monday announced that the Food and Drug Administration…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- themarketsdaily.com5
- stocktitan.net2
- defenseworld.net1
- femtechinsider.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.